Details for Patent: 9,144,609
✉ Email this page to a colleague
Which drugs does patent 9,144,609 protect, and when does it expire?
Patent 9,144,609 protects PROLENSA and is included in one NDA.
This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 9,144,609
Title: | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Abstract: | An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. An embodiment of said liquid preparation does not include any preservative. Said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). |
Inventor(s): | Sawa; Shirou (Hyogo, JP), Fujita; Shuhei (Hyogo, JP), Baklayan; George A. (Huntington Beach, CA), Padilla; Angeliqueo E. (Aliso Viejo, CA) |
Assignee: | SENJU PHARMACEUTICAL CO., LTD. (Osaka, JP) |
Application Number: | 14/269,692 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,144,609 |
Patent Claim Types: see list of patent claims | Compound; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 9,144,609
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb | PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168-001 | Apr 5, 2013 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,144,609
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2003-012427 | Jan 21, 2003 |
International Family Members for US Patent 9,144,609
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 1586316 | ⤷ Subscribe | C300494 | Netherlands | ⤷ Subscribe |
European Patent Office | 1586316 | ⤷ Subscribe | 11C0031 | France | ⤷ Subscribe |
European Patent Office | 1586316 | ⤷ Subscribe | 1190018-0 | Sweden | ⤷ Subscribe |
European Patent Office | 1586316 | ⤷ Subscribe | SPC/GB11/054 | United Kingdom | ⤷ Subscribe |
European Patent Office | 1586316 | ⤷ Subscribe | 122011100019 | Germany | ⤷ Subscribe |
European Patent Office | 1586316 | ⤷ Subscribe | 2011C/027 | Belgium | ⤷ Subscribe |
European Patent Office | 1586316 | ⤷ Subscribe | C 2011 004 | Romania | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |